Thyrocare Technologies Ltd (IN:THYROCARE)
:THYROCARE
Want to see IN:THYROCARE full AI Analyst Report?
Top Page
Thyrocare Technologies Ltd
(THYROCARE)
Select Model
Select Model
Rating:73Outperform
Price Target:
₹541.00
▲(17.84% Upside)
Action:Upgraded
Date:05/10/26
The score is driven primarily by strong financial quality (low leverage, improving returns, and solid cash generation). Technicals support the uptrend but are overheated, increasing short-term risk. High valuation (elevated P/E) meaningfully caps the overall score despite the dividend yield.
Positive Factors
Low Leverage
A very low debt-to-equity (~0.09) gives durable financial flexibility, lowering refinancing and solvency risk. This conservatism supports continued capex for automation, resilience through cyclical downturns, and optionality for acquisitions or shareholder returns without stressing liquidity.
Negative Factors
Margin Volatility
Sharp swings in gross and net margins across years create uncertainty about sustainable profitability. For a high-volume diagnostics model, volatile margins weaken predictability of cash flows, complicate capacity planning and pricing strategy, and raise the execution bar for management.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
A very low debt-to-equity (~0.09) gives durable financial flexibility, lowering refinancing and solvency risk. This conservatism supports continued capex for automation, resilience through cyclical downturns, and optionality for acquisitions or shareholder returns without stressing liquidity.
Read all positive factors
Thyrocare Technologies Ltd (THYROCARE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹74.23B
Dividend Yield0.68%
Average Volume (3M)56.30K
Price to Earnings (P/E)34.0
Beta (1Y)0.60
Revenue Growth20.61%
EPS Growth78.25%
CountryIN
Employees1,693
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)24.16
Shares Outstanding159,165,310
10 Day Avg. Volume44,587
30 Day Avg. Volume56,302
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)9.48
Price to Sales (P/S)6.69
P/FCF Ratio28.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.9
Revenue Forecast (FY)₹9.67B
Thyrocare Technologies Ltd Business Overview & Revenue Model
Company Description
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates in three segments: Diagnostic Testing Services, Imaging Services, and Others. The company conducts various medical d...
How the Company Makes Money
Thyrocare makes money mainly by charging for diagnostic tests processed in its laboratories. Its revenue model is built around high-volume, standardized pathology testing supported by centralized labs and an extensive sample collection and logisti...
Thyrocare Technologies Ltd Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
88
Very Positive
Cash Flow
84
Very Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.63B | 8.29B | 6.87B | 5.72B | 5.27B | 5.89B |
| Gross Profit | 5.90B | 4.13B | 4.96B | 1.81B | 3.63B | 4.19B |
| EBITDA | 2.45B | 2.62B | 2.04B | 1.48B | 1.31B | 2.64B |
| Net Income | 1.28B | 1.63B | 915.10M | 707.60M | 644.90M | 1.76B |
Balance Sheet | ||||||
| Total Assets | 6.80B | 7.47B | 6.93B | 6.44B | 6.33B | 6.08B |
| Cash, Cash Equivalents and Short-Term Investments | 1.92B | 2.20B | 1.92B | 1.77B | 1.51B | 1.39B |
| Total Debt | 246.80M | 506.90M | 246.80M | 423.40M | 233.10M | 207.00M |
| Total Liabilities | 1.46B | 1.61B | 1.46B | 1.16B | 975.00M | 810.90M |
| Stockholders Equity | 5.34B | 5.86B | 5.47B | 5.27B | 5.34B | 5.27B |
Cash Flow | ||||||
| Free Cash Flow | 1.11B | 1.95B | 1.46B | 1.06B | 856.60M | 755.80M |
| Operating Cash Flow | 1.27B | 2.16B | 1.91B | 1.68B | 1.29B | 1.13B |
| Investing Cash Flow | 47.10M | -260.80M | -525.20M | -912.80M | -389.90M | -235.70M |
| Financing Cash Flow | -1.18B | -1.70B | -1.30B | -848.00M | -861.80M | -894.10M |
Thyrocare Technologies Ltd Technical Analysis
Positive
459.10
Price Trends
405.43
Positive
416.88
Positive
427.38
Positive
Market Momentum
19.09
Positive
61.77
Neutral
44.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:THYROCARE, the sentiment is Positive. The current price of 459.1 is above the 20-day moving average (MA) of 449.48, above the 50-day MA of 405.43, and above the 200-day MA of 427.38, indicating a bullish trend. The MACD of 19.09 indicates Positive momentum. The RSI at 61.77 is Neutral, neither overbought nor oversold. The STOCH value of 44.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:THYROCARE.
Thyrocare Technologies Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹74.23B | 34.04 | ― | 0.68% | 20.61% | 78.25% | |
72 Outperform | ₹107.56B | 44.11 | ― | 0.21% | 23.64% | 29.96% | |
71 Outperform | ₹125.83B | 52.62 | ― | 0.20% | 19.49% | 20.50% | |
68 Neutral | ₹27.86B | 24.44 | ― | 0.92% | 25.09% | -5.52% | |
58 Neutral | ₹18.23B | 38.37 | ― | 0.38% | 9.88% | 6.01% | |
57 Neutral | ₹23.51B | 20.54 | ― | 0.49% | 1.02% | -24.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:THYROCARE
Thyrocare Technologies Ltd
466.35
135.02
40.75%
IN:KRSNAA
Krsnaa Diagnostics Limited
562.00
-80.19
-12.49%
IN:MEDIASSIST
Medi Assist Healthcare Services Limited
372.95
-132.35
-26.19%
IN:METROPOLIS
Metropolis Healthcare Ltd.
518.80
105.61
25.56%
IN:MOREPENLAB
Morepen Laboratories Limited
42.90
-23.46
-35.35%
IN:VIJAYA
Vijaya Diagnostic Centre Ltd.
1,224.90
291.38
31.21%
Thyrocare Technologies Ltd Corporate Events
Thyrocare Publishes Audited FY26 Results in Line with SEBI Norms
May 9, 2026
Thyrocare Technologies Ltd has published its audited financial results for the quarter and full year ended March 31, 2026 in leading Marathi and English newspapers, in line with SEBI’s Listing Regulations. The company has also provided a QR ...
Thyrocare Receives ₹2.03 Crore Tax Demand, Plans to Contest
Mar 29, 2026
Thyrocare Technologies has disclosed that it received a notice of demand from the Income Tax Department’s Assessment Unit under Section 156 of the Income-tax Act for Assessment Year 2024-25, raising a tax demand of ₹2,02,82,260. The co...
Thyrocare boosts Tanzania subsidiary with fresh capital infusion
Feb 24, 2026
Thyrocare Technologies Ltd has infused an additional USD 475,000, equivalent to about INR 4.33 crore, into its Tanzanian subsidiary, Thyrocare Laboratories (Tanzania) Ltd, by subscribing to compulsorily convertible irredeemable preference shares. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.